Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
BioPharma DiveBioPharma Dive staffNovember 6, 2026
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.